HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JNJ-10311795

a potent dual inhibitor of neutrophil cathepsin G and mast cell chymase; structure in first source

Also Known As:

RWJ-355871

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - JNJ-10311795: 1
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - JNJ-10311795: 1

Experts

1.	Abraham, William M: 1 article (02/2010)
2.	Andrade-Gordon, Patricia: 1 article (02/2010)
3.	Greco, Michael N: 1 article (02/2010)
4.	Haertlein, Barbara J: 1 article (02/2010)
5.	Maryanoff, Bruce E: 1 article (02/2010)
6.	Wells, Grace I: 1 article (02/2010)
7.	de Garavilla, Lawrence: 1 article (02/2010)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 02/01/2010 - "We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of Cat G and chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. "
2.	Inflammation (Inflammations) 02/01/2010 - "The preclinical antiinflammatory effects of RWJ-355871 in these animal models of inflammation indicate that this dual inhibitor may have therapeutic utility for treating airway inflammatory diseases involving mechanisms that depend on Cat G and/or chymase." 02/01/2010 - "In a murine tobacco-smoke model of airway inflammation, the effect of RWJ-355871 on smoke-induced neutrophilia was determined. " 02/01/2010 - "We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of Cat G and chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. "
3.	Asthma (Bronchial Asthma) 02/01/2010 - "In a sheep asthma model, antigen-induced airway responses were assessed with and without aerosol treatment with RWJ-355871. " 02/01/2010 - "We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of Cat G and chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. "

Related Drugs and Biologics

1.	Chymases (Chymase)
2.	Smoke
3.	Antigens
4.	Aerosols